Evolus to Report Second Quarter Financial Results on July 31, 2024
17 Julho 2024 - 9:00AM
Business Wire
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a
focus on building an aesthetic portfolio of consumer brands, today
announced that it will report its second quarter 2024 financial
results on Wednesday, July 31, 2024, after the U.S. financial
markets close.
Evolus management will host a conference call and live webcast
to discuss these results at 4:30 p.m. ET that same day. A
question-and-answer session will follow management’s remarks.
To participate in the conference call, dial (877) 407-6184
(U.S.) or (201) 389-0877 (international) or connect live via
webcast on the Investor Relations page of the Evolus website
here.
Following the completion of the call, a telephonic replay can be
accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415
(international) and using conference number 13747672. An archived
webcast can also be accessed on the Investor Relations page of the
Evolus website at www.evolus.com.
About Evolus, Inc.
Evolus (NASDAQ: EOLS) is a global performance beauty company
evolving the aesthetic neurotoxin market for the next generation of
beauty consumers through its unique, customer-centric business
model and innovative digital platform. Our mission is to become a
global, multi-product aesthetics company based on our flagship
product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only
neurotoxin dedicated exclusively to aesthetics and manufactured in
a state-of-the-art facility using Hi-Pure™ technology. Evolus is
expanding its product portfolio having entered into a definitive
agreement to be the exclusive U.S. distributor of Evolysse™, and
the exclusive distributor in Europe of Estyme®, a line of unique
dermal fillers currently in late-stage development. Visit us at
www.evolus.com, and follow us on LinkedIn, X, Instagram or
Facebook.
Jeuveau® and Nuceiva®, are registered trademarks and Evolysse™
is a trademark of Evolus, Inc. Hi-Pure™ is a trademark of Daewoong
Pharmaceutical Co, Ltd. Estyme® is a trademark of Symatese
Aesthetics S.A.S.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240717426159/en/
Investors: Nareg Sagherian, Vice
President, Head of Global Investor Relations and Corporate
Communications Phone: (248) 202-9267 Email: ir@evolus.com
Media: Email: media@evolus.com
Evolus (NASDAQ:EOLS)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Evolus (NASDAQ:EOLS)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
